Tan, Wan Ling and Chua, Kevin L. M. and Lin, Chia-Chi and Lee, Victor H. F. and Tho, Lye Mun and Chan, Anthony W. and Ho, Gwo Fuang and Reungwetwattana, Thanyanan and Yang, James C. and Kim, Dong-Wan and Soo, Ross A. and Ahn, Yong Chan and Onishi, Hiroshi and Ahn, Myung-Ju and Mok, Tony S. K. and Tan, Daniel S. W. and Yang, Fan (2020) Asian thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC. Journal of Thoracic Oncology, 15 (3). pp. 324-343. ISSN 1556-0864, DOI https://doi.org/10.1016/j.jtho.2019.10.022.
Full text not available from this repository.Abstract
Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA-C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades, contemporary considerations include the impact of different molecular subsets of NSCLC, and the roles of tyrosine kinase inhibitors post-definitive therapy and of immune checkpoint inhibitors following chemoradiotherapy. With rapid evolution of diagnostic algorithms and expanding treatment options, the need for interdisciplinary input involving multiple specialists (medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and thoracic surgeons) has become increasingly important. The unique demographics of Asian NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources including molecular testing, prompting the need for critical review of existing data and identification of current gaps. In this expert consensus statement by the Asian Thoracic Oncology Research Group, an interdisciplinary group of experts representing Hong Kong, Korea, Japan, Taiwan, Singapore, Thailand, Malaysia, and Mainland China was convened. Standard clinical practices for stage III NSCLC across different Asian countries were discussed from initial diagnosis and staging through to multi-modality approaches including surgery, chemotherapy, radiation, targeted therapies, and immunotherapy. (C) 2019 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.
| Item Type: | Article |
|---|---|
| Funders: | AstraZeneca |
| Uncontrolled Keywords: | Asian; Consensus statement; Stage III NSCLC |
| Subjects: | R Medicine R Medicine > RF Otorhinolaryngology |
| Divisions: | Universiti Malaya Medical Centre (UMMC) |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 06 Nov 2024 01:50 |
| Last Modified: | 06 Nov 2024 01:50 |
| URI: | http://eprints.um.edu.my/id/eprint/36863 |
Actions (login required)
 |
View Item |
